A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid

Trial Profile

A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2015

At a glance

  • Drugs Delafloxacin (Primary) ; Aztreonam; Linezolid; Vancomycin
  • Indications Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Sponsors Melinta Therapeutics
  • Most Recent Events

    • 17 Dec 2015 Results published in the Journal of Antimicrobial Chemotherapy
    • 06 Sep 2012 Results were presented in a late-breaking abstract at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), according to a Rib-X Pharmaceuticals media release.
    • 16 Dec 2011 Primary endpoint 'Clinical-cure-rate' has been met for delafloxacin versus vancomycin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top